Quarterly ResultMay 15, 2026, 04:13 PM
China Pharma Q1 Net Loss $1.14M; Going Concern Doubt Raised
AI Summary
China Pharma Holdings reported a net loss of $1.14 million for the first quarter of 2026, with revenue declining to $0.98 million. The company disclosed substantial doubt about its ability to continue as a going concern, citing low cash reserves and an accumulated deficit. During the quarter, China Pharma significantly increased its intangible assets by acquiring two invention patents for a total of $14.99 million, financed through the issuance of 25 million common shares.
Key Highlights
- Substantial doubt raised about the Company's ability to continue as a going concern.
- Net loss for Q1 2026 was $1.14 million, compared to $0.79 million in Q1 2025.
- Revenue decreased to $0.98 million in Q1 2026 from $1.14 million in Q1 2025.
- Gross profit was $0.29 million in Q1 2026, an improvement from a $0.14 million loss in Q1 2025.
- Acquired Topiroxostat Nanoemulsion patent for $7.81 million by issuing 12.4M shares.
- Acquired Prinsepia Utilis Esterol Sublingual Tablets patent for $7.18 million by issuing 12.6M shares.
- Basic and diluted loss per share was $(0.04) for Q1 2026, compared to $(0.24) in Q1 2025.
- Cash and cash equivalents stood at $0.17 million as of March 31, 2026.
Price Impact